No profile data available.
Novavax, Inc. (NVAX) is a healthcare company in the antiviral pharmaceuticals industry, based in Gaithersburg, United States, with about 749 full-time employees.
It reported revenue of $682.16 million for fiscal year 2024, up 22.6% from fiscal year 2023, and net income of -$187.50 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $70.45 million, down 16.6% from a year before. Rest of North America was its largest region in fiscal year 2025, with 51% of revenue. Its market capitalization was $2.10 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Novavax reported $682.16 million in revenue for fiscal year 2024, up 22.6% from $556.38 million in fiscal year 2023. In Q3 2025 revenue was $70.45 million.
Rest of North America: 51% of revenue by region in fiscal year 2025, followed by United States (36%).
$2.10 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), BioNTech SE (BNTX), Vir Biotechnology, Inc. (VIR).